Lilly confirms date and conference call for first-quarter 2026 financial results announcement

Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2026 financial results on April 30, 2026.

Rhea-AI Summary

Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2026 financial results on April 30, 2026. A conference call with investors, media and the public will begin at 10:00 a.m. Eastern that day and will be webcast live.

According to the company, a replay of the webcast will be posted on the investor website at https://investor.lilly.com/webcasts-and-presentations following the call.

Argus Apr 16 session

-0.11% close to close Open Argus

Details

News Market Reaction – LLY

In the Apr 16 session, LLY declined 0.11%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timing for Lilly’s first-quarter 2026 financial results on April 30, 2026...

Analysis

This announcement sets the timing for Lilly’s first-quarter 2026 financial results on April 30, 2026, along with a 10 a.m. Eastern conference call and webcast access details. Historically, similar conferences/earnings notices have preceded varied but often positive stock moves, with an average change of about 3.9%. Investors may contextualize the upcoming report against 2025 performance disclosed in recent proxies, including $65.2 billion in revenue, strong EPS metrics, and a 40% total shareholder return.

Key Figures

2025 Revenue: $65.2 billion 2025 GAAP EPS: $22.95 2025 Non-GAAP EPS: $24.21 +5 more

2025 Revenue

$65.2 billion

Reported in 2026 DEF 14A proxy for full-year 2025

2025 GAAP EPS

$22.95

Reported EPS for 2025 in DEF 14A

2025 Non-GAAP EPS

$24.21

Non-GAAP EPS for 2025 in DEF 14A

2025 TSR

40%

2025 total shareholder return vs S&P 500 and peers

Annual bonus payout

218%

2025 incentive plan annual bonus payout level

3-year award payout

200%

Payout on three-year shareholder value and relative value awards

Renewable electricity

80%

Approximate share of renewable electricity used in 2025

Director grant price

$989.12 per share

Reference price for multiple director stock-based awards on Mar 16, 2026

Previous Conferences,earnings Reports

5 past events · Latest: Jan 21

Same Type 5 events

1. Jan 21

   Earnings call notice

   24h Move

   +3.6%

   Set Q4 2025 results date and 10 a.m. Eastern conference call details.

2. Oct 16

   Earnings call notice

   24h Move

   -0.9%

   Announced Q3 2025 results date and webcast access information.

3. Jul 24

   Earnings call notice

   24h Move

   +0.8%

   Scheduled Q2 2025 results release and investor conference call.

4. Apr 17

   Earnings call notice

   24h Move

   +14.3%

   Confirmed Q1 2025 results date and public conference call webcast.

5. Jan 23

   Earnings call notice

   24h Move

   +1.7%

   Set Q4 2024 results and 2025 guidance announcement with call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

schedule 13g/a, def 14a, pre 14a, form 4, +3 more

7 terms

schedule 13g/a regulatory

"Eli Lilly & Co — Schedule 13G/A amendment: The Vanguard Group reports 0 shares"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

def 14a regulatory

"[DEF 14A] ELI LILLY & Co Definitive Proxy Statement"

A Form 14A is a document that companies send to shareholders before important meetings, such as votes on company decisions. It provides detailed information about the topics to be discussed or voted on, helping shareholders make informed choices. This form is essential because it ensures transparency and allows investors to understand what they are approving or rejecting.

pre 14a regulatory

"[PRE 14A] ELI LILLY & Co Preliminary Proxy Statement"

A pre 14a is a preliminary proxy statement filed with regulators that acts like a draft agenda and information packet for an upcoming shareholder meeting. It outlines proposed votes — such as board elections, mergers, pay plans or other corporate actions — and gives investors an early look at the issues they will be asked to decide on. Investors watch it because it signals potential changes to company control or strategy and can affect share price before a final version is issued.

form 4 regulatory

"[Form 4] ELI LILLY & Co Insider Trading Activity"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

View in glossary

total shareholder return financial

"along with a 40% 2025 total shareholder return that exceeded the S&P 500"

Total shareholder return is the overall gain an investor gets from owning a stock, combining changes in the share price plus any cash payouts like dividends, and assuming those payouts are reinvested in more shares. Investors use it like a single score that shows the true return on their investment—similar to checking both the growth of a savings account and the interest earned—to compare how well different companies or investments perform over time.

non-gaap eps financial

"reported EPS of $22.95 and non-GAAP EPS of $24.21"

Non-GAAP EPS is a measure of a company's profit per share that excludes certain expenses or income items that are included in standard accounting reports. It is used by investors to get a clearer picture of the company's core performance, much like removing one-time costs from a personal budget to see regular spending habits. This adjusted figure helps investors compare companies more consistently and understand their ongoing profitability.

proxy statement regulatory

"[DEF 14A] ELI LILLY & Co Definitive Proxy Statement"

A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2026 financial results on April 30, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.  

The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Refer to:	Ashley Hennessey; gentry_ashley_jo@lilly.com; 317-416-4363 (Media)
	Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors)

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-confirms-date-and-conference-call-for-first-quarter-2026-financial-results-announcement-302743261.html

SOURCE Eli Lilly and Company

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Eli Lilly (LLY) announce first-quarter 2026 results?

Lilly will publicly report its Q1 2026 financial results on April 30, 2026 at a scheduled time. According to the company, a conference call and live webcast will occur that day starting at 10 a.m. Eastern, with a replay available on its investor website.

How can investors access the April 30, 2026 LLY conference call?

Investors can access the April 30, 2026 LLY conference call via a live webcast on Lilly's investor website. According to the company, the webcast link will be posted at https://investor.lilly.com/webcasts-and-presentations and a replay will be available after the call online.

What time does the Eli Lilly (LLY) Q1 2026 conference call start on April 30?

The LLY first-quarter 2026 conference call will begin at 10 a.m. Eastern on April 30, 2026. According to the company, the session is open to investors, media and the public via webcast, and a replay will be posted on its investor site.

Will Eli Lilly (LLY) provide a replay of the April 30, 2026 conference call?

Yes. Lilly will make a replay of the April 30, 2026 conference call available on its investor website. According to the company, the replay link will be posted on https://investor.lilly.com/webcasts-and-presentations and remain accessible following the call for investors.

Will management discuss detailed Q1 2026 financial performance on the LLY call?

Yes. Lilly will discuss the company's first-quarter 2026 financial performance during the April 30, 2026 conference call. According to the company, management will detail results for investors and media during the webcast starting at 10 a.m. Eastern, with replay afterward.